Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ZYDUS LIFESCIENCES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ZYDUS LIFESCIENCES GSK PHARMA/
ZYDUS LIFESCIENCES
 
P/E (TTM) x 51.6 22.7 227.8% View Chart
P/BV x 8.1 2.8 288.2% View Chart
Dividend Yield % 7.0 0.5 1,334.6%  

Financials

 GSK PHARMA   ZYDUS LIFESCIENCES
EQUITY SHARE DATA
    GSK PHARMA
Mar-22
ZYDUS LIFESCIENCES
Mar-22
GSK PHARMA/
ZYDUS LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,917674 284.5%   
Low Rs1,400331 423.0%   
Sales per share (Unadj.) Rs193.5149.1 129.8%  
Earnings per share (Unadj.) Rs22.522.7 98.9%  
Cash flow per share (Unadj.) Rs26.529.7 89.3%  
Dividends per share (Unadj.) Rs90.002.50 3,600.0%  
Avg Dividend yield %5.40.5 1,090.4%  
Book value per share (Unadj.) Rs157.2166.1 94.7%  
Shares outstanding (eoy) m169.411,023.74 16.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x8.63.4 254.4%   
Avg P/E ratio x73.822.1 333.8%  
P/CF ratio (eoy) x62.616.9 369.9%  
Price / Book Value ratio x10.63.0 348.8%  
Dividend payout %400.411.0 3,639.7%   
Avg Mkt Cap Rs m280,960514,277 54.6%   
No. of employees `000NANA-   
Total wages/salary Rs m6,10221,777 28.0%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m32,780152,652 21.5%  
Other income Rs m7582,354 32.2%   
Total revenues Rs m33,538155,006 21.6%   
Gross profit Rs m7,73534,427 22.5%  
Depreciation Rs m6827,130 9.6%   
Interest Rs m201,270 1.6%   
Profit before tax Rs m7,79028,381 27.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,9835,117 77.8%   
Profit after tax Rs m3,80823,264 16.4%  
Gross profit margin %23.622.6 104.6%  
Effective tax rate %51.118.0 283.6%   
Net profit margin %11.615.2 76.2%  
BALANCE SHEET DATA
Current assets Rs m37,080122,614 30.2%   
Current liabilities Rs m16,98478,394 21.7%   
Net working cap to sales %61.329.0 211.6%  
Current ratio x2.21.6 139.6%  
Inventory Days Days9193 98.2%  
Debtors Days Days22980 286.1%  
Net fixed assets Rs m8,121144,382 5.6%   
Share capital Rs m1,6941,024 165.4%   
"Free" reserves Rs m24,936168,972 14.8%   
Net worth Rs m26,630169,996 15.7%   
Long term debt Rs m03,621 0.0%   
Total assets Rs m45,201266,996 16.9%  
Interest coverage x391.323.3 1,676.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.6 126.8%   
Return on assets %8.59.2 92.2%  
Return on equity %14.313.7 104.5%  
Return on capital %29.317.1 171.7%  
Exports to sales %00-   
Imports to sales %27.014.3 188.5%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,85321,869 40.5%   
Fx inflow Rs m52863,065 0.8%   
Fx outflow Rs m8,85321,869 40.5%   
Net fx Rs m-8,32541,196 -20.2%   
CASH FLOW
From Operations Rs m8,10721,041 38.5%  
From Investments Rs m-4,05511,544 -35.1%  
From Financial Activity Rs m-5,242-8,683 60.4%  
Net Cashflow Rs m-1,19023,729 -5.0%  

Share Holding

Indian Promoters % 0.0 75.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 12.6 16.2 77.5%  
FIIs % 2.3 2.5 90.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 25.0 99.9%  
Shareholders   120,127 370,396 32.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   CIPLA    SUN PHARMA    DR. REDDYS LAB    LUPIN    AUROBINDO PHARMA    


More on GSK Pharma vs Cadila Healthcare

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

GSK Pharma vs Cadila Healthcare Share Price Performance

Period GSK Pharma Cadila Healthcare S&P BSE HEALTHCARE
1-Day 3.17% -1.10% 1.20%
1-Month -1.51% 6.98% -3.18%
1-Year -17.66% 18.32% -7.59%
3-Year CAGR -0.57% 19.36% 16.43%
5-Year CAGR 0.85% 3.22% 9.40%

* Compound Annual Growth Rate

Here are more details on the GSK Pharma share price and the Cadila Healthcare share price.

Moving on to shareholding structures...

The promoters of GSK Pharma hold a 75.0% stake in the company. In case of Cadila Healthcare the stake stands at 75.0%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of GSK Pharma and the shareholding pattern of Cadila Healthcare.

Finally, a word on dividends...

In the most recent financial year, GSK Pharma paid a dividend of Rs 90.0 per share. This amounted to a Dividend Payout ratio of 400.4%.

Cadila Healthcare paid Rs 2.5, and its dividend payout ratio stood at 11.0%.

You may visit here to review the dividend history of GSK Pharma, and the dividend history of Cadila Healthcare.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Ends 378 Points Higher | Nifty Ends Above 17,850 | Paytm & Adani Enterprises Rally 15% Sensex Today Ends 378 Points Higher | Nifty Ends Above 17,850 | Paytm & Adani Enterprises Rally 15%(Closing)

After opening the day on a positive note, Indian share markets continued their momentum as the session progressed and ended higher.